Surgery for NSCLC in the era of personalized medicine

摘要: The discovery in 2004 of activating mutations the EGFR gene opened era personalized medicine thoracic oncology. Treatment with drugs that target typically results dramatic tumour response compared conventional chemotherapy patients non-small-cell lung cancer. Subsequently, newer driver oncogenes such as ALK, ROS1 and RET have been discovered. Nevertheless, surgery has become safer less invasive past 10-15 years. In medicine, surgeons to think about their evolving roles. this article, we discuss four topics relevant issue. Firstly, value surgical specimens opposed biopsy for further understanding biology is discussed. Secondly, extended indication targeted therapy considered. Thirdly, clinical trials examine neoadjuvant selected by appropriate biomarkers, important role highlighted. Finally, possibility personalizing procedure itself according cancer subtypes defined biomarkers reviewed.